Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New type of drug significantly increases survival of bladder cancer patients

A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust.

13 Feb 2021

The Future of Environmental and Food Monitoring

NewsMed interviews Professor Antje Baeumner about the future of food and environmental monitoring, the subject of her 2021 Pittcon presentation.

From Pittcon 12 Feb 2021

Scientists demonstrate how glue points and sequence alignment information can flag residue SARS-CoV-2 variants

Researchers in the U.S. have demonstrated how dominant energetic landscape mappings or glue points, along with sequence alignment information can potentially identify key residue mutations and spike protein deletions tied with emerging variants.

12 Feb 2021

People previously infected with COVID-19 respond strongly to one dose of Pfizer vaccine

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those previously infected with SARS-CoV-2 is still not completely understood.

12 Feb 2021

New technology can help develop diagnostic tests for multiple sclerosis

Multiple sclerosis (MS) is the most common neurological disease in young adults, affecting more than 2 million individuals worldwide, with about 1500 cases in Estonia. About 20% of MS patients experience optic neuritis (ON) as the presenting symptom, but not all ON patients develop MS.

12 Feb 2021

SARS-CoV-2 evolves antibody resistance in immunocompromised patient

Researchers in the United States who tracked the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient found that convalescent plasma therapy was associated with the emergence of viral variants that were less susceptible to neutralizing antibodies.

11 Feb 2021

New gut microbiome-based approach may have translational potential for cancer immunotherapy

Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice.

11 Feb 2021

COVID-19 immunity study to enroll college students to test vaccine effectiveness

A University of Arizona Health Sciences study that is examining COVID-19 immunity and re-infection among frontline workers is expanding to include some Arizona college students while broadening its research focus to include COVID-19 vaccination effectiveness.

11 Feb 2021

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization.

10 Feb 2021

Freiburg immunologists decipher anti-cancer drug's mode of operation

Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works.

10 Feb 2021

Researchers identify top-performing COVID-19 POC tests

After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified 5 direct (antigen/RNA) tests for detection of acute infection and 6 indirect (antibody) tests for detection of prior infection that meet the recently published World Health Organization (WHO) "desirable" Target Product Profile (TPP) criteria.

10 Feb 2021

Some COVID-19 patients experience persistent chronic fatigue six months after infection, finds study

Scientists from Germany recently revealed that almost 50% of patients present with moderate to severe chronic fatigue syndrome six months after SARS-CoV-2 infection.

10 Feb 2021

Taking Advantage of Measuring Molecular Collisional Cross-Sections in Pharma

News-Medical talks to Mike Greig, Director of Pharma at Bruker, about why measuring collisional cross-sections is beneficial to developing new drugs.

From Bruker Daltonics 10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Researchers at Northwestern University have noted high rates of asymptomatic and mild infection in a large community-based cohort and low levels of anti-SARS-CoV-2 immunoglobulin G antibody (IgG) in the general population of previously exposed people.

10 Feb 2021

UCI Health creates new system to deliver monoclonal antibodies in COVID-19 patients

Monoclonal antibodies are showing promise for improving outcomes for COVID-19 patients, but when a hospital is already beyond capacity, administering them can be a challenge.

10 Feb 2021

UIC researchers receive $10.15 million grant to develop treatment for dry eye conditions

Researchers at University of Illinois Chicago have been awarded a five-year, $10.15 million grant to develop a broad-spectrum immunomodulatory eye drop to treat patients with severe dry eye and ocular surface disease due to inflammatory and immune system disorders.

9 Feb 2021

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants.

9 Feb 2021

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Researchers at NYU Grossman School of Medicine in New York have conducted a study demonstrating the effectiveness of the Pfizer-BioNtech BNT162b2 vaccine against recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Feb 2021

Antibody News and Research

Further Reading

New type of drug significantly increases survival of bladder cancer patients

The Future of Environmental and Food Monitoring

Scientists demonstrate how glue points and sequence alignment information can flag residue SARS-CoV-2 variants

People previously infected with COVID-19 respond strongly to one dose of Pfizer vaccine

New technology can help develop diagnostic tests for multiple sclerosis

SARS-CoV-2 evolves antibody resistance in immunocompromised patient

New gut microbiome-based approach may have translational potential for cancer immunotherapy

COVID-19 immunity study to enroll college students to test vaccine effectiveness

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Freiburg immunologists decipher anti-cancer drug's mode of operation

Researchers identify top-performing COVID-19 POC tests

Some COVID-19 patients experience persistent chronic fatigue six months after infection, finds study

Taking Advantage of Measuring Molecular Collisional Cross-Sections in Pharma

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

UCI Health creates new system to deliver monoclonal antibodies in COVID-19 patients

UIC researchers receive $10.15 million grant to develop treatment for dry eye conditions

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo